

CPC COOPERATIVE PATENT CLASSIFICATION

A HUMAN NECESSITIES

HEALTH; AMUSEMENT

A61 MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

NOTES

1. This subclass is for secondary classification in the sense of paragraph 107bis of the Guide to the IPC. Therefore, the classification symbols of this subclass are not listed first when assigned to patent documents. Secondary classification symbols may be assigned for either invention information or additional information, as appropriate.
2. This subclass covers therapeutic activity of chemical compounds or medicinal preparations already classified as such in subclasses [A61K](#) or [C12N](#), or in classes [C01](#), [C07](#) or [C08](#).
3. In this subclass, the term "drugs" covers chemical compounds or compositions with therapeutic activity.
4. Attention is drawn to cases where the subject of the invention concerns only specific therapeutic activity of chemical compounds or medical preparations, and the chemical structure, compound, mixture or composition of this subject of the invention is known. In such cases, classification is made in both subclass [A61K](#) and subclass [A61P](#) as invention information. In addition, if the chemical structure, compound, mixture or composition or any individual ingredient of a mixture or composition is considered to represent information of interest for search, it may also be classified as additional information.

1/00	Drugs for disorders of the alimentary tract or the digestive system	5/06	. of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
1/02	. Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis	5/08	. . for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
1/04	. for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants	5/10	. of the posterior pituitary hormones, e.g. oxytocin, ADH
1/06	. Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia	5/12	. . for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
1/08	. for nausea, cinetosis or vertigo; Antiemetics	5/14	. of the thyroid hormones, e.g. T3, T4
1/10	. Laxatives	5/16	. . for decreasing, blocking or antagonising the activity of the thyroid hormones
1/12	. Antidiarrhoeals	5/18	. of the parathyroid hormones
1/14	. Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antifatulents	5/20	. . for decreasing, blocking or antagonising the activity of PTH
1/16	. for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics	5/22	. . for decreasing, blocking or antagonising the activity of calcitonin
1/18	. for pancreatic disorders, e.g. pancreatic enzymes	5/24	. of the sex hormones
3/00	Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00)	5/26	. . Androgens
3/02	. Nutrients, e.g. vitamins, minerals	5/28	. . Antiandrogens
3/04	. Anorexiant; Antiobesity agents	5/30	. . Oestrogens
3/06	. Antihyperlipidemics	5/32	. . Antioestrogens
3/08	. for glucose homeostasis (pancreatic hormones A61P 5/48)	5/34	. . Gestagens
3/10	. . for hyperglycaemia, e.g. antidiabetics	5/36	. . Antigestagens
3/12	. for electrolyte homeostasis	5/38	. of the suprarenal hormones
3/14	. . for calcium homeostasis (vitamin D A61P 3/02 ; parathyroid hormones A61P 5/18 ; calcitonin A61P 5/22 ; osteoporosis A61P 19/10 ; bone metastasis A61P 35/04)	5/40	. . Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
5/00	Drugs for disorders of the endocrine system	5/42	. . for decreasing, blocking or antagonising the activity of mineralocorticosteroids
5/02	. of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin	5/44	. . Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
5/04	. . for decreasing, blocking or antagonising the activity of the hypothalamic hormones	5/46	. . for decreasing, blocking or antagonising the activity of glucocorticosteroids
		5/48	. of the pancreatic hormones

5/50	. . for increasing or potentiating the activity of insulin	17/02	. for treating wounds, ulcers, burns, scars, keloids, or the like
7/00	Drugs for disorders of the blood or the extracellular fluid	17/04	. Antipruritics
7/02	. Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors	17/06	. Antipsoriatics
7/04	. Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents	17/08	. Antiseborrheics
7/06	. Antianaemics	17/10	. Anti-acne agents
7/08	. Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P 27/04)	17/12	. Keratolytics, e.g. wart or anti-corn preparations
7/10	. Antioedematous agents; Diuretics	17/14	. for baldness or alopecia
7/12	. Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P 5/10)	17/16	. Emollients or protectives, e.g. against radiation
9/00	Drugs for disorders of the cardiovascular system	17/18	. Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q 17/00)
9/02	. Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives	19/00	Drugs for skeletal disorders
9/04	. Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure	19/02	. for joint disorders, e.g. arthritis, arthrosis
9/06	. Antiarrhythmics	19/04	. for non-specific disorders of the connective tissue
9/08	. Vasodilators for multiple indications	19/06	. Antigout agents, e.g. antihyperuricemic or uricosuric agents
9/10	. for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis	19/08	. for bone diseases, e.g. rachitism, Paget's disease
9/12	. Antihypertensives	19/10	. . for osteoporosis
9/14	. Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers	21/00	Drugs for disorders of the muscular or neuromuscular system
11/00	Drugs for disorders of the respiratory system	21/02	. Muscle relaxants, e.g. for tetanus or cramps
11/02	. Nasal agents, e.g. decongestants	21/04	. for myasthenia gravis
11/04	. for throat disorders	21/06	. Anabolic agents (androgens A61P 5/26)
11/06	. Antiasthmatics	23/00	Anaesthetics
11/08	. Bronchodilators	23/02	. Local anaesthetics
11/10	. Expectorants	25/00	Drugs for disorders of the nervous system
11/12	. Mucolytics	25/02	. for peripheral neuropathies
11/14	. Antitussive agents	25/04	. Centrally acting analgesics, e.g. opioids
11/16	. Central respiratory analeptics	25/06	. Antimigraine agents
13/00	Drugs for disorders of the urinary system	25/08	. Antiepileptics; Anticonvulsants
13/02	. of urine or of the urinary tract, e.g. urine acidifiers	25/10	. . for petit-mal
13/04	. for urolithiasis	25/12	. . for grand-mal
13/06	. Anti-spasmodics	25/14	. for treating abnormal movements, e.g. chorea, dyskinesia
13/08	. of the prostate	25/16	. . Anti-Parkinson drugs
13/10	. of the bladder	25/18	. Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
13/12	. of the kidneys	25/20	. Hypnotics; Sedatives
15/00	Drugs for genital or sexual disorders (for disorders of sex hormones A61P 5/24); Contraceptives	25/22	. Anxiolytics
15/02	. for disorders of the vagina	25/24	. Antidepressants
15/04	. for inducing labour or abortion; Uterotonics	25/26	. Psychostimulants, e.g. nicotine, cocaine
15/06	. Antiabortive agents; Labour repressants	25/28	. for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
15/08	. for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis	25/30	. for treating abuse or dependence
15/10	. for impotence	25/32	. . Alcohol-abuse
15/12	. for climacteric disorders	25/34	. . Tobacco-abuse
15/14	. for lactation disorders, e.g. galactorrhoea	25/36	. . Opioid-abuse
15/16	. Masculine contraceptives	27/00	Drugs for disorders of the senses
15/18	. Feminine contraceptives	27/02	. Ophthalmic agents
17/00	Drugs for dermatological disorders	27/04	. . Artificial tears; Irrigation solutions
		27/06	. . Antiglaucoma agents or miotics
		27/08	. . Mydriatics or cycloplegics
		27/10	. . for accommodation disorders, e.g. myopia
		27/12	. . for cataracts
		27/14	. . Decongestants or antiallergics
		27/16	. Otologicals

- 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]**
- 29/02 . without antiinflammatory effect
- 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics**
- 31/02 . Local antiseptics
- 31/04 . Antibacterial agents
- 31/06 . . for tuberculosis
- 31/08 . . for leprosy
- 31/10 . Antimycotics
- 31/12 . Antivirals
- 31/14 . . for RNA viruses
- 31/16 . . . for influenza or rhinoviruses
- 31/18 . . . for HIV
- 31/20 . . for DNA viruses
- 31/22 . . . for herpes viruses
- 33/00 Antiparasitic agents**
- 33/02 . Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- 33/04 . . Amoebicides
- 33/06 . . Antimalarials
- 33/08 . . for Pneumocystis carinii
- 33/10 . Anthelmintics
- 33/12 . . Schistosomicides
- 33/14 . Ectoparasiticides, e.g. scabicides
- 35/00 Antineoplastic agents**
- 35/02 . specific for leukemia
- 35/04 . specific for metastasis
- 37/00 Drugs for immunological or allergic disorders**
- 37/02 . Immunomodulators
- 37/04 . . Immunostimulants
- 37/06 . . Immunosuppressants, e.g. drugs for graft rejection
- 37/08 . Antiallergic agents ([antiasthmatic agents A61P 11/06](#); [ophthalmic antiallergics A61P 27/14](#))
- 39/00 General protective or antinoxious agents**
- 39/02 . Antidotes
- 39/04 . Chelating agents
- 39/06 . Free radical scavengers or antioxidants
- 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution**
- 43/00 Drugs for specific purposes, not provided for in groups [A61P 1/00-A61P 41/00](#)**

NOTE

Classification is only made in this group when a specific therapeutic activity for a chemical compound or medicinal preparation has been clearly disclosed, the specific therapeutic activity not being appropriate to any of groups [A61P 1/00 - A61P 41/00](#).